Integrating HIV and hEART health in South Africa (iHeart-SA)

在南非整合艾滋病毒和心脏抗逆转录病毒治疗 (iHeart-SA)

• 批准号: 10841100
• 负责人: Mohammed Kumail Ali
• 金额: $ 30万
• 依托单位: WITS HEALTH CONSORTIUM (PTY), LTD
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-25 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10841100
• 关键词: Address; Adoption; Blood Pressure; Cardiac health; Cardiovascular Diseases; Caring; Clinic; Communities; Country; Diabetes Mellitus; Diagnosis; Disease; Doctor of Philosophy; Documentation; Effectiveness; Evidence based intervention; Feedback; Goals; Government; Guidelines; HIV; Health care facility; Home; Hypertension; India; Institution; Intervention; Measures; Methods; Modification; Monitor; Motivation; National Heart, Lung, and Blood Institute; Output; Ownership; Patients; Persons; Provider; Publications; Randomized, Controlled Trials; Research Methodology; Review Literature; Risk; Risk Factors; Self Management; Site; South Africa; Stroke; Testing; Training; antiretroviral therapy; cluster trial; comorbidity; cost; design; experience; heart disease risk; human centered design; hypertension control; implementation science; improved; innovation; meetings; multidisciplinary; next generation; pandemic disease; patient-level barriers; primary outcome; programs; provider-level barriers; rural health clinic; scale up; screening; success; support tools; system-level barriers; treatment strategy

ABSTRACT Our multidisciplinary, multi-country team of implementation science experts propose to adapt, implement, and evaluate the “Integrating HIV and hEART health in South Africa” (iHeart-SA) program that incorporates hypertension (HTN) and diabetes (DM) screening and treatment for people living with HIV (PLWH). SA is the epicenter of the HIV pandemic worldwide with over 7 million PLWH, of whom ~5 million are treated with anti- retroviral therapies (ART). ART rollout has two relevant repercussions: first, PLWH now have approximately twice the risk of developing HTN, DM, and cardiovascular disease (CVD); and second, the success of ART programs creates a corresponding mandate to deliver integrated, high-quality, sustainable treatment strategies to detect, treat, and control HTN and DM in HIV care. There are patient-, provider-, and system-level barriers to achieving these goals; but, there are also evidence-based interventions to address them, and we have extensive experience applying these to transform care for CVD co-morbidities in South Africa and India. We have determined the barriers to CVD care and reviewed the literature to select a package of interventions proven successful in randomized controlled trials, including: use of non-clinician care coordinators to support treatment documentation and quality improvement (QI); incorporation of home monitoring to enhance self- management; decision-support tools to facilitate treatment initiation and modifications; and monthly audit / feedback meetings to support continuous QI. We will use the EPIS framework and partner with government, academic, facility, and community stakeholders to guide the project by: Exploring (engaging stakeholders in human-centered design to co-adapt the intervention package to align with local capacity, opportunities, and motivations, Aim UG1); Preparing (strengthening capacity in implementation science, Aim UG2); Implementing and evaluating the intervention package via a stepped wedge cluster trial and assessing both implementation (e.g., reach, adoption, fidelity) and effectiveness (e.g., controlled blood pressure [primary outcome] among PLWH and HTN), Aim UH1; measuring Sustainability and costs after 24 months (where 12 months were spent transferring delivery from study to local staff (Aim UH2); and developing a strategy to scale up to rural clinics and nationally (Aim UH3). The overall goal of this project is to employ rigorous empirical methods to develop and test care innovations that expand the scope of HIV care in a sustainable, scalable, and impactful way. We will employ an achievable milestone plan to deliver high quality outputs, including: continued stakeholder relationships and co-ownership of the study over the project period; completion of three PhDs in implementation science; and disseminating findings via high-impact publications and presentations. We will also participate in NHLBI’s collaborative multi-institution network designed to strengthen research methods and impacts across all sites, and to advance training of the next generation of scientific leaders.

抽象的 我们的多学科，多国实施科学专家团队建议适应，实施和 评估包含的“南非综合艾滋病毒和心脏健康”（IHEART-SA）计划 HIV患者（PLWH）的高血压（HTN）和糖尿病（DM）筛查和治疗。 SA是 全球艾滋病毒大流行的中心，有超过700万PLWH，其中约有500万次治疗 逆转录病毒疗法（ART）。艺术推出具有两个相关的影响：首先，PLWH现在大约有 患有HTN，DM和心血管疾病（CVD）的风险两倍；其次，艺术的成功 计划创建了相应的任务，以提供综合，高质量，可持续的治疗策略 在HIV护理中检测，治疗和控制HTN和DM。有患者，提供者和系统级别的障碍 实现这些目标；但是，也有基于证据的干预措施来解决这些干预措施，我们有 经过丰富的经验，用于改变南非和印度CVD合并症的护理。我们 已经确定了CVD护理的障碍，并审查了文献以选择一揽子干预措施 在随机对照试验中证明了成功 治疗文件和质量改进（QI）；合并家庭监控以增强自我 管理;促进治疗计划和修改的决策支持工具；和每月审核 / 反馈会议以支持连续气。我们将使用EPIC框架和与政府合作， 学术，设施和社区利益相关者指导该项目：探索（与利益相关者参与 以人为本的设计共同适应干预套件，以与当地的能力，机会和 动机，目标UG1）；准备（增强实施科学的能力，AIM UG2）； 通过阶梯楔形集群试验和评估实施和评估干预套件 实施（例如，覆盖范围，适应，保真度）和有效性（例如，受控血压[主要 结果]在PLWH和HTN中），AIM UH1；测量24个月后的可持续性和成本（其中12个 花了几个月的时间将从学习转移到当地员工（AIM UH2）；并制定扩展策略 到农村诊所和全国范围（AIM UH3）。该项目的总体目标是采用严格的经验 开发和测试护理创新的方法，以可持续，可扩展， 和有影响力的方式。我们将采用可实现的里程碑计划来提供高质量的产出，包括： 在整个项目期间，持续的利益相关者关系和研究共同拥有；完成三个 实施科学博士；并通过高影响的出版物和演示来传播发现。 我们还将参加NHLBI的合作多机构网络，旨在加强研究 所有站点的方法和影响，以及进步对下一代科学领导者的培训。

项目成果

Comparative performance of cardiovascular risk prediction models in people living with HIV.

• DOI: 10.4102/sajhivmed.v23i1.1395
• 发表时间: 2022
• 期刊: SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE
• 影响因子: 1.7
• 作者: Tahir, Irtiza S.;Vos, Alinda G.;Damen, Johanna A. A.;Barth, Roos E.;Tempelman, Hugo A.;Grobbee, Diederick E.;Scheuermaier, Karine;Venter, Willem D. F.;Klipstein-Grobusch, Kerstin
• 通讯作者: Klipstein-Grobusch, Kerstin

Weight gain stopping/switch rules for antiretroviral clinical trials.

抗逆转录病毒临床试验的体重增加停止/转换规则。

• DOI: 10.1097/qad.0000000000003221
• 发表时间: 2022
• 期刊: AIDS (London, England)
• 作者: Kouamou,Vinie;Inzaule,Seth;Manasa,Justen
• 通讯作者: Manasa,Justen